iSpecimen Inc.(ISPC)Earnings, Financials & Key Ratios
ISPC•NASDAQ
$5.29
$734580 mkt cap·Price updated May 7, 2026
AboutiSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.Show more
- Revenue$2M-79.2%
- EBITDA-$7M+43.3%
- Net Income-$10M+16.1%
- EPS (Diluted)-91.20+87.0%
- Gross Margin1.25%-97.1%
- EBITDA Margin-375.69%-173.0%
- Operating Margin-465.42%-239.7%
- Net Margin-543.68%-304.2%
- ROE-327.77%-71.2%
- Debt/Equity0.09-7.7%
- Interest Coverage-5375.89-9236.6%
ISPC Key Insights
iSpecimen Inc. (ISPC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.2x book value
✗Weaknesses
- ✗Profits declining 17.7% over 5 years
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 3 (bottom 3%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Sales declining 25.1% over 5 years
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ISPC Price & Volume
iSpecimen Inc. (ISPC) stock price & volume — 10-year historical chart
Loading chart...
ISPC Growth Metrics
iSpecimen Inc. (ISPC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-25.1%
3 Years-42.97%
TTM-79.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.54%
Return on Capital
10 Years-126.49%
5 Years-126.49%
3 Years-175.29%
Last Year-260.99%
ISPC Peer Comparison
iSpecimen Inc. (ISPC) competitors in Lab Consumables and Sample Preparation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 BRLT | 222.95M | 1.41 | -5.64 | 3.63% | -2.62% | -13.97% | 0.48 | |
 MEDP | 12.24B | 428.71 | 28.06 | 19.97% | 17.19% | 120.89% | 0.55 | |
 BLFS | 1.13B | 23.12 | -92.48 | 16.97% | -10.52% | -2.91% | 0.05 | |
 ICLR | 9.54B | 125.00 | 13.12 | 1.99% | 7.4% | 6.32% | 0.38 | |
 CRL | 8.98B | 181.94 | -62.52 | -0.85% | -4.59% | -5.68% | 0.95 | |
 LMAT | 2.46B | 107.91 | 42.82 | 13.53% | 24.35% | 16.19% | 0.47 | |
 QDEL | 733.24M | 10.77 | -0.65 | -1.89% | -45.57% | -56.31% | 1.46 | |
 NTRA | 31.16B | 219.82 | -144.62 | 35.9% | -9.03% | -15.28% | 0.13 |
Compare ISPC vs Peers
iSpecimen Inc. (ISPC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ISPC Income Statement
iSpecimen Inc. (ISPC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.39M | 4.3M | 8.18M | 11.14M | 10.4M | 9.93M | 9.29M | 1.93M |
| Revenue Growth % | - | -2.2% | 90.4% | 36.06% | -6.58% | -4.56% | -6.42% | -79.24% |
| Cost of Goods Sold | 2.36M | 2.13M | 3.59M | 5.25M | 4.76M | 4.82M | 5.3M | 1.9M |
| COGS % of Revenue | 53.76% | 49.5% | 43.81% | 47.14% | 45.73% | 48.55% | 57.07% | 98.75% |
| Gross Profit | 2.03M▲ 0% | 2.17M▲ 6.8% | 4.6M▲ 111.9% | 5.89M▲ 28.0% | 5.65M▼ 4.1% | 5.11M▼ 9.5% | 3.99M▼ 21.9% | 24.11K▼ 99.4% |
| Gross Margin % | 46.24% | 50.5% | 56.19% | 52.86% | 54.27% | 51.45% | 42.93% | 1.25% |
| Gross Profit Growth % | - | 6.8% | 111.87% | 28% | -4.09% | -9.52% | -21.92% | -99.4% |
| Operating Expenses | 5.39M | 6.05M | 7.01M | 11.81M | 15.83M | 16.28M | 16.72M | 9M |
| OpEx % of Revenue | 122.61% | 140.76% | 85.59% | 106.07% | 152.19% | 163.95% | 179.92% | 466.67% |
| Selling, General & Admin | 3.51M | 4.26M | 5.04M | 9.4M | 12.37M | 11.68M | 12.65M | 5.77M |
| SG&A % of Revenue | 79.76% | 99.21% | 61.61% | 84.41% | 118.95% | 117.64% | 136.13% | 299% |
| Research & Development | 1.21M | 993.33K | 1.47M | 1.84M | 2.66M | 3.57M | 3.53M | 0 |
| R&D % of Revenue | 27.53% | 23.11% | 17.9% | 16.5% | 25.54% | 35.93% | 38% | - |
| Other Operating Expenses | 41.73K | 792.78K | 497.18K | 573.91K | 801.13K | 1.03M | 537.89K | 3.23M |
| Operating Income | -3.36M▲ 0% | -3.88M▼ 15.6% | -2.41M▲ 38.0% | -5.93M▼ 146.2% | -10.19M▼ 71.9% | -11.17M▼ 9.7% | -12.73M▼ 14.0% | -8.98M▲ 29.5% |
| Operating Margin % | -76.37% | -90.27% | -29.4% | -53.21% | -97.92% | -112.5% | -136.99% | -465.42% |
| Operating Income Growth % | - | -15.61% | 37.98% | -146.23% | -71.91% | -9.65% | -13.96% | 29.46% |
| EBITDA | -2.89M | -3.25M | -1.59M | -4.92M | -8.98M | -9.1M | -12.78M | -7.25M |
| EBITDA Margin % | -65.69% | -75.5% | -19.39% | -44.2% | -86.34% | -91.7% | -137.6% | -375.69% |
| EBITDA Growth % | - | -12.4% | 51.11% | -210.16% | -82.49% | -1.37% | -40.43% | 43.31% |
| D&A (Non-Cash Add-back) | 469.17K | 634.97K | 819.69K | 1M | 1.21M | 2.07M | -56.47K | 1.73M |
| EBIT | -4.26M | -3.16M | -2.56M | -6.86M | -10.01M | -10.87M | -12.67M | -10.48M |
| Net Interest Income | -1.21M | -1.72M | -2.1M | -2.09M | -69.62K | 108.97K | -175.94K | 1.8K |
| Interest Income | 1.5K | 630 | 437 | 11.4K | 169.34K | 339.75K | 44.13K | 3.75K |
| Interest Expense | 1.21M | 1.72M | 2.1M | 2.1M | 238.96K | 230.78K | 220.07K | 1.95K |
| Other Income/Expense | -2.12M | -1M | -2.25M | -3.04M | -59.84K | 69.86K | 230.24K | -1.51M |
| Pretax Income | -5.47M▲ 0% | -4.88M▲ 10.8% | -4.65M▲ 4.7% | -8.96M▼ 92.6% | -10.25M▼ 14.3% | -11.1M▼ 8.3% | -12.5M▼ 12.6% | -10.49M▲ 16.1% |
| Pretax Margin % | -124.56% | -113.63% | -56.84% | -80.48% | -98.5% | -111.8% | -134.51% | -543.68% |
| Income Tax | -127K | -157K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 2.32% | 3.21% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -5.35M▲ 0% | -4.73M▲ 11.6% | -4.65M▲ 1.6% | -8.96M▼ 92.6% | -10.25M▼ 14.3% | -11.1M▼ 8.3% | -12.5M▼ 12.6% | -10.49M▲ 16.1% |
| Net Margin % | -121.67% | -109.97% | -56.84% | -80.48% | -98.5% | -111.8% | -134.51% | -543.68% |
| Net Income Growth % | - | 11.6% | 1.59% | -92.64% | -14.33% | -8.33% | -12.6% | 16.09% |
| Net Income (Continuing) | -5.35M | -4.73M | -4.65M | -8.96M | -10.25M | -11.1M | -12.5M | -10.49M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4564.40▲ 0% | -4039.60▲ 11.5% | -5775.20▼ 43.0% | -980.40▲ 83.0% | -817.60▲ 16.6% | -982.00▼ 20.1% | -703.20▲ 28.4% | -91.20▲ 87.0% |
| EPS Growth % | - | 11.5% | -42.96% | 83.02% | 16.61% | -20.11% | 28.39% | 87.03% |
| EPS (Basic) | -4564.40 | -4039.60 | -5775.20 | -980.40 | -818.80 | -49.20 | -703.20 | -91.20 |
| Diluted Shares Outstanding | 1.17K | 1.17K | 1.17K | 10.22K | 11.05K | 11.3K | 17.77K | 115.06K |
| Basic Shares Outstanding | 1.17K | 1.17K | 1.17K | 10.22K | 11.04K | 11.3K | 17.77K | 115.06K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
ISPC Balance Sheet
iSpecimen Inc. (ISPC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 2.3M | 1.58M | 3.47M | 32.95M | 19.68M | 8.24M | 3.59M | 6.95M |
| Cash & Short-Term Investments | 1.13M | 53.89K | 695.91K | 27.74M | 15.31M | 5.01M | 1.88M | 6.88M |
| Cash Only | 1.13M | 53.89K | 695.91K | 27.74M | 15.31M | 2.34M | 1.88M | 6.88M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 2.66M | 0 | 0 |
| Accounts Receivable | 1.03M | 1.39M | 2.36M | 4.88M | 3.93M | 2.94M | 1.44M | 48.3K |
| Days Sales Outstanding | 85.2 | 118.26 | 105.19 | 160.04 | 137.75 | 108.12 | 56.75 | 9.14 |
| Inventory | 47.29K | 54.91K | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 7.31 | 9.42 | - | - | - | - | - | - |
| Other Current Assets | 0 | 79.23K | 0 | 0 | 140.87K | 292.08K | 264.89K | 25.46K |
| Total Non-Current Assets | 1.74M | 2.63M | 2.74M | 2.77M | 4.94M | 7.58M | 5.76M | 2.58M |
| Property, Plant & Equipment | 149.1K | 119.92K | 75.59K | 32.78K | 410.54K | 321.64K | 421.54K | 294.7K |
| Fixed Asset Turnover | 29.48x | 35.84x | 108.27x | 339.69x | 25.34x | 30.87x | 22.04x | 6.55x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.44M | 2.31M | 2.63M | 2.71M | 4.5M | 7.23M | 5.33M | 1M |
| Long-Term Investments | 127K | 179.52K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 154.6K | 207.12K | 27.6K | 27.6K | 27.6K | 27.6K | 12.1K | 1.28M |
| Total Assets | 4.04M▲ 0% | 4.21M▲ 4.2% | 6.21M▲ 47.3% | 35.72M▲ 475.2% | 24.62M▼ 31.1% | 15.82M▼ 35.7% | 9.35M▼ 40.9% | 9.53M▲ 1.9% |
| Asset Turnover | 1.09x | 1.02x | 1.32x | 0.31x | 0.42x | 0.63x | 0.99x | 0.20x |
| Asset Growth % | - | 4.2% | 47.34% | 475.22% | -31.08% | -35.74% | -40.89% | 1.94% |
| Total Current Liabilities | 11.3M | 15.76M | 22.14M | 2.51M | 4.28M | 6.05M | 5.77M | 6.23M |
| Accounts Payable | 696.91K | 737.79K | 1.79M | 832.68K | 2.46M | 3.93M | 4.2M | 5.36M |
| Days Payables Outstanding | 107.67 | 126.55 | 182.47 | 57.9 | 188.68 | 297.24 | 288.93 | 1.03K |
| Short-Term Debt | 6.97M | 10.59M | 12.59M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 864.91K | 2.22M | 873.25K | 654.75K | 0 | 415.77K | 360.71K | 192.53K |
| Other Current Liabilities | 2.77M | 2.21M | 2.37M | 0 | 132.34K | 0 | 0 | 0 |
| Current Ratio | 0.20x | 0.10x | 0.16x | 13.15x | 4.60x | 1.36x | 0.62x | 1.12x |
| Quick Ratio | 0.20x | 0.10x | 0.16x | 13.15x | 4.60x | 1.36x | 0.62x | 1.12x |
| Cash Conversion Cycle | -15.17 | 1.12 | - | - | - | - | - | - |
| Total Non-Current Liabilities | 11.17M | 11.17M | 11.35M | 3.42M | 27.4K | 29.13K | 268.8K | 211.87K |
| Long-Term Debt | 0 | 0 | 178.9K | 3.42M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 27.4K | 29.13K | 268.8K | 211.87K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 11.17M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 22.47M | 26.93M | 33.49M | 5.93M | 4.31M | 6.08M | 6.04M | 6.44M |
| Total Debt | 6.97M | 10.59M | 12.77M | 3.42M | 185.85K | 196.24K | 312.17K | 268.8K |
| Net Debt | 5.84M | 10.54M | 12.07M | -24.32M | -15.12M | -2.15M | -1.57M | -6.61M |
| Debt / Equity | - | - | - | 0.11x | 0.01x | 0.02x | 0.09x | 0.09x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | -3.51x | -1.83x | -1.22x | -3.26x | -41.88x | -47.09x | -57.58x | -5375.89x |
| Total Equity | -18.42M▲ 0% | -22.72M▼ 23.3% | -27.28M▼ 20.1% | 29.79M▲ 209.2% | 20.31M▼ 31.8% | 9.74M▼ 52.0% | 3.31M▼ 66.0% | 3.09M▼ 6.7% |
| Equity Growth % | - | -23.31% | -20.07% | 209.21% | -31.83% | -52.04% | -66.01% | -6.73% |
| Book Value per Share | -15733.35 | -19417.73 | -23314.50 | 2916.17 | 1837.10 | 861.89 | 186.32 | 26.84 |
| Total Shareholders' Equity | -18.42M | -22.72M | -27.28M | 29.79M | 20.31M | 9.74M | 3.31M | 3.09M |
| Common Stock | 537 | 537 | 94 | 873 | 892 | 908 | 170 | 848 |
| Retained Earnings | -19.75M | -24.41M | -29.06M | -38.02M | -48.27M | -59.36M | -71.86M | -82.35M |
| Treasury Stock | -172 | -172 | -172 | -172 | -172 | -172 | -172 | -172 |
| Accumulated OCI | -159.83K | 0 | 0 | 0 | 0 | 840 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ISPC Cash Flow Statement
iSpecimen Inc. (ISPC) cash flow — operating, investing & free cash flow history
| Line item | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -2.68M | -2.68M | -288.38K | -10.67M | -5.82M | -5.81M | -8.26M | -4.24M |
| Operating CF Margin % | -61.02% | -62.35% | -3.52% | -95.81% | -55.93% | -58.5% | -88.94% | -219.83% |
| Operating CF Growth % | - | 0.07% | 89.24% | -3599.43% | 45.47% | 0.17% | -42.29% | 48.68% |
| Net Income | -5.35M | -4.73M | -4.65M | -8.96M | -10.25M | -11.1M | -12.5M | -10.49M |
| Depreciation & Amortization | 469.17K | 634.97K | 819.69K | 1M | 1.21M | 2.12M | 2.29M | 1.66M |
| Stock-Based Compensation | 113.92K | 360.38K | 92.87K | 622.06K | 678.61K | 459.67K | 249.68K | 21.27K |
| Deferred Taxes | 946K | -551K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 767.72K | 551.99K | 410.53K | 1.95M | 190.22K | 127.75K | 2.19M | 2.45M |
| Working Capital Changes | 368.49K | 1.05M | 3.04M | -5.28M | 2.35M | 2.59M | -502.67K | 2.11M |
| Change in Receivables | -393.19K | 192.25K | -894.47K | -2.68M | 709.18K | 820.61K | -397.4K | 1.34M |
| Change in Inventory | -12.66K | -7.62K | 0 | 0 | 0 | 0 | 0 | 45.11K |
| Change in Payables | 584.05K | 40.88K | 1.05M | -959.75K | 1.63M | 1.47M | 272.12K | 1.24M |
| Cash from Investing | -1.03M | -1.48M | -1.1M | -1.04M | -3.19M | -7.23M | 1.98M | -1M |
| Capital Expenditures | -1.03M | -1.48M | -426 | -2.55K | -215.5K | -19.48K | -31.55K | -454 |
| CapEx % of Revenue | 23.34% | 34.32% | 0.01% | 0.02% | 2.07% | 0.2% | 0.34% | 0.02% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -969.68K | -1.45M | -1.1M | -1.04M | -2.98M | -4.73M | -678.29K | -5M |
| Cash from Financing | 3.52M | 3.08M | 2.03M | 38.75M | -3.42M | 70.89K | 5.82M | 10.24M |
| Debt Issued (Net) | 2.17M | 3.08M | 2.03M | 1M | -3.5M | 0 | 0 | 0 |
| Equity Issued (Net) | -41 | 0 | 0 | 41.5M | 0 | 0 | 1.89M | 10.24M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -41 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 1.34M | 3.67K | 0 | -3.75M | 78.64K | 70.89K | 3.93M | 0 |
| Net Change in Cash | -192.08K▲ 0% | -1.08M▼ 460.4% | 642.02K▲ 159.6% | 27.04M▲ 4112.2% | -12.43M▼ 146.0% | -12.97M▼ 4.3% | -465.26K▲ 96.4% | 5M▲ 1175.2% |
| Free Cash Flow | -3.71M▲ 0% | -4.16M▼ 12.1% | -1.39M▲ 66.5% | -11.71M▼ 741.6% | -9.01M▲ 23.0% | -10.55M▼ 17.1% | -8.3M▲ 21.4% | -4.24M▲ 48.9% |
| FCF Margin % | -84.36% | -96.67% | -17% | -105.13% | -86.61% | -106.28% | -89.28% | -219.86% |
| FCF Growth % | - | -12.08% | 66.52% | -741.58% | 23.04% | -17.13% | 21.39% | 48.87% |
| FCF per Share | -3166.00 | -3551.41 | -1188.88 | -1145.88 | -814.92 | -933.65 | -466.79 | -36.86 |
| FCF Conversion (FCF/Net Income) | 0.50x | 0.57x | 0.06x | 1.19x | 0.57x | 0.52x | 0.66x | 0.40x |
| Interest Paid | 0 | 0 | 0 | 2.82M | 161.58K | 16K | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ISPC Key Ratios
iSpecimen Inc. (ISPC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -713.06% | -40.9% | -73.87% | -191.51% | -327.77% |
| Return on Invested Capital (ROIC) | - | - | - | - | -143.31% | -131.1% | -204.45% | - |
| Gross Margin | 46.24% | 50.5% | 56.19% | 52.86% | 54.27% | 51.45% | 42.93% | 1.25% |
| Net Margin | -121.67% | -109.97% | -56.84% | -80.48% | -98.5% | -111.8% | -134.51% | -543.68% |
| Debt / Equity | - | - | - | 0.11x | 0.01x | 0.02x | 0.09x | 0.09x |
| Interest Coverage | -3.51x | -1.83x | -1.22x | -3.26x | -41.88x | -47.09x | -57.58x | -5375.89x |
| FCF Conversion | 0.50x | 0.57x | 0.06x | 1.19x | 0.57x | 0.52x | 0.66x | 0.40x |
| Revenue Growth | - | -2.2% | 90.4% | 36.06% | -6.58% | -4.56% | -6.42% | -79.24% |
ISPC Frequently Asked Questions
iSpecimen Inc. (ISPC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
iSpecimen Inc. (ISPC) reported $1.9M in revenue for fiscal year 2025. This represents a 56% decrease from $4.4M in 2018.
iSpecimen Inc. (ISPC) saw revenue decline by 79.2% over the past year.
iSpecimen Inc. (ISPC) reported a net loss of $10.5M for fiscal year 2025.
Dividend & Returns
iSpecimen Inc. (ISPC) has a return on equity (ROE) of -327.8%. Negative ROE indicates the company is unprofitable.
iSpecimen Inc. (ISPC) had negative free cash flow of $4.2M in fiscal year 2025, likely due to heavy capital investments.
Explore More ISPC
iSpecimen Inc. (ISPC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates